An adult male patient with multiple adenomas and a hepatocellular carcinoma : mild Gycogen Storage Disease type Ia by Cassiman, David et al.
                             Elsevier Editorial System(tm) for Journal of Hepatology 
                                  Manuscript Draft 
 
 
Manuscript Number: JHEPAT-D-09-00326R1 
 
Title: An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild Glycogen 
Storage Disease type Ia  
 
Article Type: Case Report 
 
Keywords: Glycogen Storage Disease, adenomatosis, beta-catenin, adult 
 
Corresponding Author: Dr. David Cassiman, M.D., Ph.D. 
 
Corresponding Author's Institution: KULeuven 
 
First Author: David Cassiman, M.D., Ph.D. 
 
Order of Authors: David Cassiman, M.D., Ph.D.; Louis Libbrecht, M.D., Ph.D.; Chris Verslype, M.D., Ph.D. ; 
Wouter Meersseman, M.D., Ph.D. ; Roberto Troisi, M.D., Ph.D. ; Jessica Zucman-Rossi, M.D., Ph.D.; Hans 
Van Vlierberghe, M.D., Ph.D. 
 
Abstract: The development of hepatocellular adenomas and - more rarely - carcinoma in the liver of 
patients with Glycogen Storage Disease type Ia (GSDIa) is a well-known complication of the disease. 
The pathophysiology of adenoma and carcinoma development in these patients is, however, hitherto 
largely unknown and is thought to be related to the metabolic control of the patient and/or the type of 
mutations in the G6PC gene. We report here on a very illustrative case of adenoma and carcinoma 
formation in a previously undiagnosed 42 year old male GSDIa patient (enzymatically and genetically 
proven). He had 2 episodes of mild hypoglycaemia in childhood, never required formal treatment, 
showed normal growth, only mild lactate increases after prolonged starvation. He was a long-distance 
runner for most of his adult life, without the need for more than normal carbohydrate intake 
before/during exertion. To gain a better view on the type of carcinoma formed in this patient, 
molecular studies were performed. We show here that in this patient with mild GSDIa without 
recurrent hypoglycaemic episodes adenoma and carcinoma formation still occurred and that 
malignant transformation of adenoma here is associated with CTNNB1 mutations and a typical mRNA 
profile of a beta-catenin activated lesion. 
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ABSTRACT 
The development of hepatocellular adenomas and – more rarely – carcinoma 
in the liver of patients with Glycogen Storage Disease type Ia (GSDIa) is a 
well-known complication of the disease. The pathophysiology of adenoma and 
carcinoma development in these patients is, however, hitherto largely 
unknown and is thought to be related to the metabolic control of the patient 
and/or the type of mutations in the G6PC gene. We report here on a very 
illustrative case of adenoma and carcinoma formation in a previously 
undiagnosed 42 year old male GSDIa patient (enzymatically and genetically 
proven). He had 2 episodes of mild hypoglycaemia in childhood, never 
required formal treatment, showed normal growth, only mild lactate increases 
after prolonged starvation. He was a long-distance runner for most of his adult 
life, without the need for more than normal carbohydrate intake before/during 
exertion. To gain a better view on the type of adenoma formed in this patient, 
molecular studies were performed. We show here that in this patient with mild 
GSDIa without recurrent hypoglycaemic episodes adenoma and carcinoma 
formation still occurred and that malignant transformation of adenoma here is 
associated with CTNNB1 mutations and a typical mRNA profile of a beta-
catenin activated lesion. 
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INTRODUCTION 
Glycogen Storage Disease type Ia (GSDIa) or Von Gierke‟s disease (OMIM 
+232200) is an autosomal recessive disease caused by mutations in the 
G6PC gene encoding for glucose-6-phosphatase, an enzyme essential in the 
mobilisation of glucose from liver glycogen during fasting. Patients with this 
disease in general present in infancy, with ketotic hypoglycaemia, lactic 
acidosis, poor growth, hepatomegaly, hyperuricemia, hypertriglyceridemia, 
renal insufficiency. Traditionally, patients have to be kept in anabolic state by 
nocturnal nasogastric tube feeding and/or ingestion of uncooked corn starch 
to prevent life-threatening hypoglycaemia and hyperlactacidemia and to 
achieve normal development and growth, for life. In the second or third 
decade, a large majority of GSDIa patients develop hepatocellular adenomas, 
some of which evolve into hepatocellular carcinoma (HCC).1,2 Because 
GSDIa is a rare disorder, the molecular subtype of the typical adenomas in 
these patients is largely unknown. On the other hand, to be able to distinguish 
adenomas associated with malignant degeneration from the adenomas that 
will not turn malignant would be very worthwhile, to allow adequate selection 
of patients with GSDIa and adenomas for tumor resection or liver 
transplantation. 
Outside the context of GSDIa, it is becoming clear that adenomas that carry 
risk of malignant transformation are those carrying CTNNB1 mutations 
leading to an activation of ß-catenin, as opposed to the steatotic adenomas 
associated with HNF1A (Hepatocyte Nuclear factor 1 alpha) mutations and 
the inflammatory adenomas associated with IL6ST mutation, activating 
gp130.3,4,5 
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Up till now, mutation analysis and chromosomal studies of a total of 13 
GSDIa-associated  adenomas have been reported. Three of these adenomas 
were CTNNB1 mutated. 3,6,7 The only adenoma associated with an HCC, was 
CTNNB1 mutated.7
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MATERIALS AND METHODS 
Patient 
The patient signed a written informed consent form, approved by the local 
Ehical Committee (Leuven University Hospitals, Belgium). 
 
Pathology 
The resection specimen was received freshly and 8 biopsies taken from the 
lesion were snap-frozen in liquid nitrogen-cooled isopentane and stored at -
80° for molecular evaluation. Standard histopathological examination and 
histochemical stains were performed as described previously.8 
Immunohistochemistry for beta-catenin and glutamine synthetase were 
performed according to a recently described protocol.9 
 
Molecular studies 
Molecular studies (CTNNB1, HNF1A and IL6ST mutation analysis and real-
time quantitative RT-PCR for LFABP1, UGT2B7, CRP, SAA, GLUL, GPR49, 
ANGPT1, ANGPT2, NTS, HAL) were performed as described, on all 8 
biopsies.3,5,7 
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CASE DESCRIPTION 
Patient history 
A 42 year old male patient presented at the outpatient clinic, with abdominal 
pain and cramps for 2 weeks. Clinically, hard hepatomegaly was noted. On 
subsequent CT scan, a large (23cm by 12cm by 14cm) lesion was detected in 
the left liver lobe, showing an irregular margin, necrotic areas and 
calcifications. On MRI with contrast, multiple focal lesions mildly hyperintense 
on T2-weighted imaging, arterially vascularised and without late retention 
were noted, the largest lesion in segment 5/6 (3.5 cm), 5 (3.0 cm), 7 (1.7 cm), 
multiple similar lesions in segments 5, 6, 7 and 8 (all smaller than 2 cm). 
Based on the radiological appearance, preference for adenomas was 
accepted. Carcino-embryonic antigen and alpha-fetoprotein were not 
determined. 
There were no metastases within or outside of the liver, so the lesion was 
resected. The patient underwent a laparoscopic left hepatectomy with 
preservation of the middle hepatic vein. This was done in a standard fashion 
using the surgical aspirator (CUSA Excel, Integra Life Science Ltd, IDA 
Business and Technology Park, Ireland) with minimal blood loss provided by 
an unilateral vascular inflow exclusion before starting the resection.The 
pathology report of the resection specimen, is described below. 
As a child, between 1 and 2 years of age, he experienced two episodes of 
syncope with suspected hypoglycaemia, during viral illness. The treatment 
consisted of oral intake of glucose. Clinically at that time there was 
hepatomegaly. A diagnosis of glycogenosis was suggested but not pursued, 
followed-up or treated accordingly. On the contrary, the patient was started on 
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a diet for celiac disease, which he was still following at the age of 42. He did 
not have a history of recurrent hypoglycaemia, nocturnal feeding, lactic 
acidosis. He had a late puberty and growth spurt but excellent catch-up 
growth to a total length of 170 cm (weight 61kg). He never experienced any 
problems with fasting or exertion, he on the contrary is a long-distance runner, 
running marathons without apparent need for extra carbohydrates before or 
during exertion. After a 12h fast, lactate was 4.49 mM (0.4-2.0; in fed state 
1.22 mM on one occasion, 2.01 mM on another), glucose after 12h fast was 
64 mg/dl (55-100), triglycerides 328 mg/dl (<=180), cholesterol 151 mg/dl 
(<=190), uric acid 5.0 mg/dL (3.5-7.2). Glycaemia measured at home in the 
mornings, in fasting state, or when feeling weak or hungry, were consistently 
normal. Creatine kinase and liver tests were normal. Echocardiography was 
normal as well as glomerular filtration rate. There was no proteinuria, there 
was no history of kidney stones. During work-up for a gastroenteritis episode, 
7 years prior to his presentation with the current lesion, ultrasound showed a 
„somewhat enlarged, homogeneous liver‟ (no pictures stored for review). 
Family history is unremarkable. There is no consanguinity. The patient has no 
children, has one healthy sister without similar complaints (routine 
biochemistry and liver ultrasound normal), both parents are alive and well 
around the age of 70. 
At 1 year follow-up after the resection, the patient has resumed his work and 
sports without restraint. A malignant lesion measuring 23 cm is well outside 
Milan criteria for transplantation. The patient has declined the theoretical 
option of transplantation. Four-monthly control MRI of the liver shows no 
recurrence of HCC and stable size of the remaining adenomas, chest CT 
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shows no lung metastases. 
 
Pathology report of the resection specimen 
The partial hepatectomy specimen measured 19 x 13 x 9 cm and contained a 
multinodular tumor with a maximal diameter of 18 cm. The tumor had a 
lightbrown color in some areas and a yellow to greenish aspect in other areas. 
Biopsies taken from the small rim of non-tumorous liver showed normal portal 
tracts and some fibrosis due to compression of the tumor. Very focally, there 
was some mixed steatosis. The periportal parenchyma contained numerous 
hepatocytes with a glycogenated nucleus (figure 1). Several hepatocytes also 
had a swollen, pale cytoplasm with wisps and small clumps of eosinophilic, 
giving the impression of so-called “plant-like” hepatocytes, which is suggestive 
of glycogen storage disease which is not of type 0 or 4 (figure 1).11 Intense 
cytoplasmic hepatocytic positivity was not seen on the PAS-staining, most 
likely due to wash-out of glycogen during processing of the tissue. 
The lesion consisted of several nodules of well differentiated hepatocellular 
carcinoma against a background of hepatocellular adenoma. The 
adenomatous areas consisted of sheets of non-steatotic hepatocytes 
organised as 1 to 2 cell thick plates separated by non-dilated sinusoids and 
traversed by some blood vessels. Reticulin surrounding these plates was 
preserved. Portal tracts, ductular reaction and inflammation were all absent. 
The nuclei of the hepatocytes showed mild atypia: they were slightly irregular 
and contained chromatin clumps and a distinctive nucleolus. Based on these 
morphological features (figure 2a), the adenoma was suspected to be of the 
beta-catenin activated subtype.9 This was confirmed by 
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immunohistochemistry for glutamine synthetase which showed diffuse and 
strong staining of the adenomatous areas (figure 3a), while the surrounding, 
non-lesional liver only showed positivity in hepatocytes surrounding 
centrolobular veins (figure 3b). Nuclear expression of beta-catenin was 
observed in only very few hepatocytes in the adenoma. Positive staining of 
the hepatocytic cell membrane for beta-catenin served as an internal control. 
The malignant nodules were sharply demarcated from the adenomatous 
areas and consisted of hepatocyte-like cells organised in trabecular and 
pseudoglandular structures. The trabecules were separated from each other 
by sinusoids and they were frequently more than 3 cells thick. The reticulin 
pattern was clearly lost. The nuclei were sometimes peripherally located 
within the cell and were slightly more atypical than in the adenomatous areas. 
The nucleo-cytoplasmic ratio was clearly increased. Bilirubin droplets were 
present in some of the malignant nodules. Based on these features (figure 
2b), the diagnosis of well differentiated hepatocellular carcinoma arising in a 
beta-catenin activated hepatocellular adenoma was established. The 
malignant areas showed diffuse and strong positivity for glutamine synthetase 
(figure 3a). While all malignant hepatocytes showed positivity of the cell 
membrane for beta-catenin, there were very few positive nuclei. 
 
Diagnostic work-up for suspected glycogenosis 
Glycogen phosphorylase kinase enzymatic activity on fresh red blood cells 
was normal. On snap-frozen liver biopsy, glycogen was 4.8% of wet liver 
weight (3.53+/-0.45), enzymatic activity of phosphorylase and hexose 
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diphosphatase were normal, glucose-6-phosphatase activity was clearly 
reduced to 0.36 U/g (7.95 +/- 0.51).  
Mutation analysis of the G6PC gene revealed compound heterozygosity for 
p.Arg170X (c.508C>T) in exon 4 and p.Ala192Val (c.575C>T) in exon 5. 
p.Arg170X has been described as a pathogenic mutation10, while p.Ala192Val 
has not, but affects a phylogenetically highly conserved amino acid in a 
transmembrane domain of the protein and is thus predicted to be pathogenic.  
 
Molecular studies of the HCC (8 biopsies) 
Four random biopsies, taken from the large malignant lesion, showed the 
same mutation in CTNNB1: in-frame deletion Del7L-131L, while 4 other 
random biopsies showed another mutation in CTNNB1: in-frame deletion 
del21G-98M + ins21CC. No IL6ST or HNF1A mutations were found in any of 
the samples. We performed RT-PCR analysis testing the expression of 10 
genes (LFABP1, UGT2B7, CRP, SAA, GLUL, GPR49, ANGPT1, ANGPT2, 
NTS, HAL) (Table 1). We found an mRNA expression profile typical of a ß-
catenin activated adenoma in all samples, with overexpression of two genes 
targeted by ß-catenin (GLUL and GPR49) when compared to normal liver 
tissues (fold change T/N ranging from 3 to 374-fold, depending of the 
biopsies). Taken together, these results clearly demonstrate the presence of 
somatic CTNNB1 in-frame deletions activating ß-catenin in this lesion. 
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DISCUSSION 
We report on a mild clinical presentation of GSDIa, where the diagnosis was 
missed early in life and the patient developed normally, without symptoms or 
complaints and without treatment or follow-up. Nevertheless, in adult age, the 
patient presented with multiple liver adenomas, one of which had developed 
into an HCC.  
In the case presented here, the presence of hepatocytes with swollen and 
pale cytoplasm and with glycogenated nuclei in the tissue surrounding the 
resected hepatocellular carcinoma, together with a vague history of 
hypoglycaemia and hepatomegaly and an increased fasting lactate, set off the 
search for an underlying glycogenosis. The fact the patient has an 
enzymatically and genetically proven GSDIa and presented with 
adenomatosis and HCC in adult age, should prompt liver specialists and 
oncologists to look for GSDIa in patients presenting with adenomatosis and/or 
HCC, even when adult. 
The presence of hepatocytes with swollen and pale cytoplasm is a well-known 
feature of GSD.11 Although glycogenated nuclei in the periportal area are 
known to represent a disturbance of glycogen metabolism, as is seen in e.g. 
NASH12, they have hitherto not been reported as a typical feature of GSD. 
Therefore, it is possible that they are related to the atypical clinical 
presentation of this patient. If not, the presence of glycogenated nuclei would 
be an additional and easy feature to prompt pathologists and clinicians to 
explore underlying glycogenoses. 
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The association of CTNNB1 mutations with malignant degeneration, is well 
known in sporadic liver adenoma.3 Out of the 13 GSDIa-associated 
adenomas reported so far, 3 were CTNNB1 mutated.3,6,7 Only one out of 13 
was associated with an HCC and was CTNNB1 mutated. We describe 
another case here, where the resected malignant lesion carried different 
CTNNB1 mutations and an mRNA expression profile typical of a beta-catenin 
activation associated lesion (Table 1).  
The discrepancy between the rarity of nuclear positivity for beta-catenin and 
the diffuse positivity for its down-stream target gene glutamine synthetase in 
the lesion described here, is remarkable. This has also been observed 
recently by Bioulac-Sage et al. in 3 CTNNB1 mutated sporadic adenomas.9 
This case report suggests that glutamine synthetase is a more sensitive 
marker than beta-catenin itself, when screening for possible beta-catenin 
mutation is performed by immunohistochemistry. This has to be studied and 
confirmed in a larger series of adenomas. 
Finally, several types of CTNNB1 mutations were present in one malignant 
lesion here and all 8 random biopsies carried CTNNB1 mutations. This 
suggests that at least two adenomas with distinct mutation types have 
undergone confluence, either before or after malignant transformation, but 
that all lesions giving rise to the malignant lesion were CTNNB1 mutated. 
 
In a setting of organ shortage and in view of the risks associated with liver 
transplantation, it would be useful to gain a better insight into the type of 
adenomas in GSDIa patients that are likely to undergo malignant 
transformation and therefore would strengthen the case for liver 
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transplantation.13 By inference from what is know about sporadic adenomas, 
one would expect these to be the CTNNB1 mutated adenomas, i.e. glutamine 
synthetase positive or beta-catenin positive on immunohistochemistry. This is 
the second case of malignant transformation of a CTNNB1-mutated GSDIa-
associated adenoma. If this association confirms itself in other patients, it 
would affect our treatment choices in these patients. 
 
In conclusion, we describe a case of mild GSDIa, presenting with liver lesions 
in adult age. The HCC resected from this patient was CTNNB1 mutated, 
which confirms the premalignant nature of CTNNB1 mutated adenomas, also 
in GSDIa. Molecular studies for CTNNB1 mutations or routine 
immunohistochemistry for glutamine synthetase and beta-catenin, performed 
on punction biopsies taken from adenomas in GSDIa livers, could be useful to 
select patients with large and/or growing lesions for transplantation. 
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FIGURE LEGENDS 
Figure 1: several hepatocytes show swollen, vacuolated nuclei. Hepatocytes 
with such glycogenated nuclei are mainly located in the area surrounding the 
portal tract (PT) (long arrows). The cytoplasm of hepatocytes frequently is 
swollen and is pale with small clumps of eosinophilic material. This “plant-like” 
aspect is most pronounced in the area indicated by the small arrow and 
enlarged in the inset. Original magnification x 400. 
 
Figure 2: the adenomatous component of the multinodular lesion consist of 
trabecules of hepatocytes that show discrete nuclear atypia. The 
morphological features are consistent with a beta-catenin activated adenoma. 
Original magnification x 200 (left) and x 400 (right). 
 
Figure 3: in contrast to the adenomatous part, the areas that transformed into 
well differentiated hepatocellular carcinoma show more distinct nuclear atypia 
and crowding due to an increased nucleo-cytoplasmic ratio and thickening of 
the trabecules. Original magnification x 400. 
 
Figure 4: Both the adenomatous areas (A) as the parts that consist of 
malignant tumor (T) show diffuse and strong cytoplasmic positivity on the 
staining for glutamine synthetase, while surrounding non-lesional tissue 
serving as internal control only shows some staining in the area around the 
centrolobular vein (CV). Original magnification x 200. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
TABLE LEGEND 
 
Table 1: Real-time quantitative RT-PCR results on the 8 biopsies taken from 
the resected lesion 
 
Nm = non mutated; M = mutated, AA = amino acid, H-HCA = adenoma 
inactivated for HNF1A, ßHCA = adenoma mutated for ß-catenin; IHCA = 
inflammatory adenoma. 
*quantitative RT-PCR data expressed in 2^-DDCT, arbitrary unit, normal 
liver=1 
**quantitative RT-PCR data, ratio of expression
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Nodules ID HNF1 
Mutation 
Mutation 
gp130 
CTNNB1 mutation 
(nucleotide) 
CTNNB1 
mutation 
(AA change) 
GLUL* LGR5* FABP1* UGT2B7* ANGPT1/ANGPT2** NTS/HAL** CRP* SAA2* 
Biopsy 1 nm nm 21_395del 7L-131Ldel 3.7 2.5 1 3.1 0.6 0.6 0.2 1.2 
Biopsy 2 nm nm 21_395del 7L-131Ldel 39.9 26.9 0.3 0.9 0.6 0.7 0.00 0.02 
Biopsy 3 nm nm 21_395del 7L-131Ldel 12.5 5.3 0.3 0.4 1.6 0.3 0,01 0.00 
Biopsy 4 nm nm 21_395del 7L-131Ldel 74.9 7.1 0.3 0.2 0.4 0.3 0.00 0.00 
Biopsy 5 nm nm 64-291del 21G-
98Mdel+insCC 
68 58 0.2 0.3 2.0 16.0 0.01 0.01 
Biopsy 6 nm nm 64-291del 21G-
98Mdel+insCC 
99.5 39.5 0.4 1 1.25 26 0.01 0.01 
Biopsy 7 nm nm 64-291del 21G-
98Mdel+insCC 
142.2 62.3 0.5 1.5 2.4 38 0.02 0.01 
Biopsy 8 nm nm 64-291del 21G-
98Mdel+insCC 
374.2 196.7 1.2 4.4 3 36 0.1 0.3 
H-HCA (n=7) M nm nm nm 1.3 0.1 0.01 0.009 4.7 3.1 1.3 0.002 
ßHCA (n=3) nm nm M M 96 56 0.6 1.7 4.3 13 0.2 0.58 
IHCA gp130 
mutated (n=6) 
nm M nm  
nm 
2.7 2.1 0.85 3 2.3 2.6 36,00 35,00 
Focal nodular 
hyperplasia (n=3) 
Nm Nm nm nm 18.4 21.8 0.3 2.3 12.1 386 0.1 0.2 
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We thank the reviewers and editors for their efforts to help us improve 
the manuscript, by detailed reading and commenting. We have fulfilled 
all requests for changes and additional information. Below, please find 
a point-by-point response to the reviewer‟s comments. 
 
Highest regards, 
 
David Cassiman 
 
 
Reviewer #1:  
 
Abstract 
-How can you say metabolic control in this patient was not the cause of 
adenoma formation?  The patient was not followed metabolically. 
 
A: this was omitted. 
 
Introduction 
-"because hepatocellular adenomas in these patients rarely require 
surgical intervention" There are a number of publications that document 
surgical intervention in patients with GSD I and adenomas. 
 
A: some centers prefer to adopt a wait-and-see strategy with careful 
radiological follow-up of the lesions, even if adenomas exceed the 
generally accepted limit of 5 cm in size. The section was omitted. 
 
Case Description 
-"As a child, between 1 and 2 years of age, he experienced two episodes 
of syncope with suspected hypoglycaemia, during viral illness. The 
treatment consisted of oral intake of glucose. Clinically at that time 
there was hepatomegaly. A diagnosis of glycogenosis was suggested but 
not proven. On the contrary, the patient was started on a diet for 
celiac disease, which he was still following at the age of 42." - We 
would argue that this was not a very mild case of GSD I.  There were 
symptoms and signs of a GSD I diagnosis and "a diagnosis of 
glycogenosis was suggested" but because of lack of knowledge and work 
up, the diagnosis was missed. 
 
A: this was changed accordingly: “A diagnosis of glycogenosis was 
suggested but not pursued, followed-up or treated accordingly.” 
 
-Did the patient have protienuria?  What were the AFP and CEA values?  
Were these lab values done? Although we know they are not helpful in 
the adenoma setting, it is critical to know if in the HCC setting how 
they different from HCC in general population 
 
A: aFP and CEA were not determined, there was no proteinuria. This was 
added. 
 
-"During work-up for a gastroenteritis episode, 7 years prior to his 
presentation with the current lesion, ultrasound showed a somewhat 
enlarged, homogeneous liver."  - Was this ultrasound re-reviewed after 
the diagnosis of HCC 7 years later?  Is it possible there were 
undetected adenomas that could be identified when re-reviewed based on 
the current diagnosis? There is a growing body of evidence that imaging 
modalities for adenomas requires MRI with contrast, thus this point 
Detailed Response to Reviewers
needs to be highlighted in discussion and conclusions. Also, 
retrospective look may shed light on what may have been missed.   
 
A: pictures were not available for review (ultrasound taken in 
emergency department setting, in a small rural hospital).  
 
-"Four-monthly control MRI of the liver shows no recurrence of HCC and 
stable size of the remaining adenomas, chest CT shows no lung 
metastases."  - Was this MRI with contrast?  What were the size of the 
adenomas? Also, given the body of literature of recurrence of adenomas, 
the role of liver transplant in this setting needs discussion.  
 
A: the requested data were added. 
 
Discussion 
-Again - we argue that this was not a "very mild" case of GSD I.  There 
were clinical symptoms and signs in the patient from an early age.  The 
patient was missed because of a lack of work up and instead treated for 
celiac disease. - not necessarily a "atypical clinical presentation" - 
maybe a milder clinical presentation.  Current literature suggests 
there is a milder/less severe end of the GSD I phenotype.  The patient 
had symptoms and in today's environment, the sypmtoms would have 
probably led to a diagnosis of GSD I. Also, the kidney involvenet- 
presence or absence of kidney stones, proteinuria and hypocitraturia 
are not mentione din teh clinical work up.  
 
A: this was changed accordingly („mild‟ instead of „very mild‟), the 
requested clinical data were added in the case description. 
 
- Hepatomegaly was said to have resolved but was documented on the scan 
7 years prior. "During work-up for a gastroenteritis episode, 7 years 
prior to his presentation with the current lesion, ultrasound showed a 
somewhat enlarged, homogeneous liver."  However, the description of the 
ultrasound findings suggest an enlarged liver.   
 
A: this passage was omitted from the discussion, as it was indeed based 
on non-reviewable data. 
 
-Would like to see a mechanistic pathway for CTNNB1, activation of ß-
catenin, etc. 
 
A: length restrictions do not allow a detailed discussion of the 
literature beyond GSDIa, but further information is available in the 
cited literature.  
 
- Discrepancy between the lack of nuclear positivity for beta-catenin 
and a weak positivity expression of its down-stream target gene 
glutamine synthetase in their case is unusual.  Thus to test this 
hypothesis further studies need to be conducted in a larger cohort of 
GSD I patients with adenomas and also cases with HCC transformation of 
adenomas already. Also, can the authors comment on immunehitochemistry 
patterns that could help predict "adenomas at risk for transformation". 
In this clinical scenario pt had frank HCC , thus findings are not 
unexpected. 
 
A: we indeed report this as „remarkable‟ and refer to another study 
where this same discrepancy is reported. The fact this needs 
confirmation in larger cohorts was added. The patterns that would 
classify adenomas as „at risk‟ are also detailed in the discussion now. 
 
- Point made by authors that they had seen 3 to 374 fold over 
expression of two down stream genes targeted by ß-catenin (GLUL and 
GPR49) in adenomas transformed HCC resected liver tissue as compared to 
normal liver tissues, it would be a good idea to show some proof of 
this statement showing RT-PCR/qPCR data obtained by the authors.   
Authors do not show any molecular or mRNA expression profile data 
obtained from this patient at all. It will be good to add some of that 
data to the paper. 
 
A: new Table 1 contains all the available data. 
 
Overall, this paper has approached the characterization of the HCC 
found in a patient using an immuno-histochemistry and other 
histopathology approaches to get a retrospective diagnosis of GSD Ia in 
this patient.  What the authors fail to mention is clinically the 
patient could have been diagnosed with GSD Ia, with appropriate FU.  
 
A: this is mentioned now, in the case description (see above, also).  
 
What did immunohistochemistry offer that routine histology did not, in 
terms of a diagnosis of HCC, Are there differences in HCC in GSD I and 
general population on immunohistochemistry? This needs to be clearly 
stated. Also what is the ease of doing these studies in a general 
setting. Are they routinely done in HCC? 
 
A: beta catenin and glutamine synthase staining of resected or biopsied 
adenomas are becoming common practice, since they allow easy 
classification of the lesion and therefore determine the follow-up and 
treatment. Immunohistochemical staining is a routine pathology lab 
technique.  
 
 
Reviewer #2:  
 
Mutation analysis of the G6PC gene revealed a previously described 
mutation and a novel one whose pathogenicity has not been proved. It 
would be useful to know whether this mutation has been searched in 
controls, so that a polymorphism may be ruled out. 
 
A: The fitting combination of clinical picture, routine blood work-up 
and blood testing after fasting, the enzymology on liver tissue, the 
liver pathology and the finding of one known mutation together with a 
mutation that is suspected to be pathogenic was considered sufficient 
to make the diagnosis. We did not check the mutation/polymorphism in 
healthy controls. 
 
In the discussion, mild GSDIa have been prviously reported with 
prolonged fasting tolerance and this point should be corrected. 
 
A: was corrected 
 
Finally, even though the paper does not focus on these points, it would 
be interesting to know whether hepatectomy was difficult or not 
(bleeding in particular),  
 A: this information was added in the case description: “The patient 
underwent a laparoscopic left hepatectomy with preservation of the 
middle hepatic vein. This was done in a standard fashion using the 
surgical aspirator (CUSA Excel, Integra Life Science Ltd, IDA Business 
and Technology Park, Ireland) with minimal blood loss provided by an 
unilateral vascular inflow exclusion before starting the resection.” 
 
and to know why the authors have not discussed liver transplantation in 
this patient, as it has been recommended when hepatocarcinoma occurs. 
 
A: this passage was added to the case description “A malignant lesion 
measuring 23 cm is well outside Milan criteria for transplantation. The 
patient has declined the theoretical option of transplantation.” 
 
